Until now, the US Food and Drug Administration (FDA) has approved two classes of medications to treat AD: (1) cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and (2) an NDMA receptor antagonist (memantine). Here, BCHE is linked to Alzheimer disease.